Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  ElectroCore, Inc.    ECOR

ELECTROCORE, INC.

(ECOR)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector news

ELECTROCORE DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In electroCore, Inc. To Contact The Firm

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/12/2019 | 10:30am EDT

New York, New York--(Newsfile Corp. - October 12, 2019) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in electroCore, Inc. (NASDAQ: ECOR) ("electroCore" or the "Company") of the November 25, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/6455/48717_42087ba6042408da_logo_lg.jpg


Faruqi & Faruqi logo

Cannot view this image? Visit:
https://orders.newsfilecorp.com/files/6455/48717_42087ba6042408da_logo_lg.jpg

If you invested in electroCore stock or options pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2018 initial public offering, and/or purchased or otherwise acquired electroCore securities between June 22, 2018 and September 25, 2019, inclusive and would like to discuss your legal rights, click here: www.faruqilaw.com/ECOR. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.

CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330

The lawsuit has been filed in the U.S. District Court for the District Court of New Jersey on behalf of all those who purchased electroCore securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's June 2018 initial public offering, and/or purchased or otherwise acquired electroCore securities between June 22, 2018 and September 25, 2019, inclusive. The case, Turnofsky v. electroCore, Inc., No. 19-cv-18400 was filed on September 26, 2019.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by failing to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the Company's lead product, gammaCore, did not enjoy any advantages over other acute treatments for migraines and episodic cluster headaches; (2) that, as a result, doctors and patients were unlikely to adopt gammaCore over existing treatments; (3) that the Company's voucher program was not effective to increase adoption of gammaCore; (4) that the Company lacked sufficient resources to successfully commercialize gammaCore; (5) that the Company's business plan and strategy was not sustainable because electroCore lacked sufficient revenue to be profitable; (6) that the Company's product registry and efforts were ineffective to initiate reimbursement policies by commercial payors for gammaCore; (7) that the lack of reimbursement would materially impact adoption and sales of gammaCore; (8) that the Company lacked sufficient clinical data demonstrating that gammaCore was effective and safe for migraine prevention; (9) that, as a result, the Company's 510(k) submission for the use of gammaCore for migraine prevention was unlikely to be approved by the FDA; and (10) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

On May 14, 2019, the Company announced first quarter 2019 financial results that fell short of investors' expectations, reporting $410,000 net sales and operating loss of $14.2 million.

On this news, electroCore's stock price fell from $5.33 per share on May 14, 2019 to $3.75 per share on May 15, 2019-a $1.58 or 29.64% drop.

Then, on September 25, 2019, the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore's 510(k) submission, which seeks an expanded indication for the use of gammaCore.

On this news, electroCore's stock price fell from $3.36 per share on September 24, 2019 to $2.57 per share on September 25, 2019-a $0.79 or 23.52% drop.

By the commencement of this action, electroCore stock was trading as low as $1.25 per share, a nearly 92% decline from the $15 per share IPO price.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.

Faruqi & Faruqi, LLP also encourages anyone with information regarding electroCore's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48717


© Newsfilecorp 2019
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on ELECTROCORE, INC.
10/12ELECTROCORE DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Suffe..
NE
10/11ELECTROCORE Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exc..
NE
10/09ELECTROCORE Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exc..
NE
10/08ELECTROCORE DEADLINE ALERT : Faruqi & Faruqi, LLP Encourages Investors Who Suffe..
NE
10/04DEADLINE REMINDER : The Law Offices of Howard G. Smith Reminds Investors of Loom..
BU
10/03KASKELA LAW LLC : Announces Investigation of electroCore, Inc. on Behalf of Inve..
BU
10/02ELECTROCORE, INC. : Change in Directors or Principal Officers, Other Events, Fin..
AQ
10/02ELECTROCORE : Glancy Prongay & Murray Reminds Investors of Looming Deadline in t..
BU
10/01SHAREHOLDER ALERT : Robbins Arroyo LLP Announces electroCore, Inc. (ECOR) Sued f..
BU
10/01ECOR CLASS ACTION DEADLINE : Bernstein Liebhard LLP Announces the Filing of a Se..
PR
More news
Financials (USD)
Sales 2019 3,78 M
EBIT 2019 -43,0 M
Net income 2019 -42,7 M
Debt 2019 -
Yield 2019 -
P/E ratio 2019 -1,32x
P/E ratio 2020 -2,02x
Capi. / Sales2019 15,4x
Capi. / Sales2020 2,84x
Capitalization 58,3 M
Chart ELECTROCORE, INC.
Duration : Period :
electroCore, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELECTROCORE, INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 9,75  $
Last Close Price 1,97  $
Spread / Highest target 458%
Spread / Average Target 395%
Spread / Lowest Target 357%
EPS Revisions
Managers
NameTitle
Francis R. Amato Chief Executive Officer & Director
Carrie Smith Cox Chairman
Michael Romaniw VP-Operations, Systems & Logistics
Brian M. Posner VP, Chief Financial & Accounting Officer
Anthony S. Fiorino Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ELECTROCORE, INC.-66.93%61
ABBOTT LABORATORIES10.09%140 738
MASIMO CORPORATION35.43%7 754
NOVOCURE LIMITED130.38%7 572
ASAHI INTECC CO., LTD.-37.87%6 719
PENUMBRA, INC.19.43%5 078